CAMBRIDGE, Mass., Feb. 1, 2024
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced that
James Porter, Ph.D., Chief Executive
Officer, and Alexandra Balcom, Chief
Financial Officer, will participate in a fireside chat during the
Guggenheim Healthcare Talks 6th Annual Biotechnology
Conference on Thursday, February 8,
2024, at 10:30 a.m. ET in
NYC.
A live webcast will be available in the Investors section of the
company's website at www.nuvalent.com, and archived for 30 days
following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage
biopharmaceutical company focused on creating precisely targeted
therapies for patients with cancer, designed to overcome the
limitations of existing therapies for clinically proven kinase
targets. Leveraging deep expertise in chemistry and structure-based
drug design, we develop innovative small molecules that have the
potential to overcome resistance, minimize adverse events, address
brain metastases, and drive more durable responses. Nuvalent is
advancing a robust pipeline with investigational candidates for
ROS1-positive, ALK-positive, and HER2-positive non-small cell lung
cancer, and multiple discovery-stage research programs.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biotechnology-conference-302050153.html
SOURCE Nuvalent, Inc.